Clover Biopharmaceuticals, Ltd. (2197.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Clover Biopharmaceuticals, Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
300
First IPO Date
November 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Joshua G. Liang | Chief Executive Officer & Executive Director | 2.27M | 1993 |
| Peng Liang | Founder, Chief Scientific Officer & Chairman of the Board | 4.45M | 1961 |
| Nicolas Burdin | Global Head of R&D | 0 | N/A |
| Igor Smolenov | Executive Vice President of Global Clinical Development Vaccines | 0 | N/A |
| Nicholas Jackson | President of Global R&D and Alliances | 0 | 1971 |
| Berry Michael | Chief Technical Operation Officer | 0 | 1966 |
| Htay Htay Han MBBS | Chief Medical Officer of Vaccine | 0 | 1969 |
| Tracy Wang | Senior Vice President of Head of Regulatory Affairs, China | 0 | N/A |
| Yang Li | Chief Technology Officer | 0 | N/A |
| LiongHo Chua | President of Greater China | 0 | 1964 |
Description
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
